Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xanodyne Pharmaceuticals, Inc.

http://www.xanodyne.com/

Latest From Xanodyne Pharmaceuticals, Inc.

Finance Watch: Rivus Raises $132m In Series B Cash To Fund Obesity Drug Trials

VC funding slowed recently, but public company financings kept up a brisk pace with follow-on public offerings for Allakos and Alpine, private placements for Ventyx and Syros, and Albireo’s royalty deal. In restructuring updates, Biogen raised $592m in a real estate deal and Acerus is assessing options.

Financing Growth

Novartis Changing Of The Guard Continues As R&D Chief Bradner Exits

A smooth handover hints at an amicable departure for Jay Bradner, but also gives CEO Vas Narasimhan the chance to refresh strategy with a new team.

Immune Disorders Cancer

Deal Watch: Ovid Teams With Gensaic On Phage-Derived, Gene-Delivered Therapies

Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.

Deal Watch Business Strategies

Genentech Licenses Prostate Cancer Drug From China-Based Jemincare

Deal Snapshot: Other major players have made headway in bispecifics for prostate cancer, while Jemincare’s drug is the latest China-developed technology to head westward.

Deals Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register